ES-SCLC is a form of lung cancer accounting for one in eight lung cancer cases in the UK. It is an aggressive disease that progresses rapidly, with a significant negative impact on the quality of ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...

Amgen has said the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) conditional approval of Imdylltra (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC) marks a “ ...

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which authors say minimizes the need for supportive care. Administered before ...

This important regulatory designation follows promising data from the ongoing global Phase 1a/1b study in patients with previously treated extensive-stage SCLC (ES-SCLC) after at least one prior ...

for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung ...

This approval establishes serplulimab as the first and only anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC. Serplulimab is the world's first anti-PD-1 mAb approved for first-line ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...